Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma

NCT07521657 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT07521657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07521657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
January 1, 2032
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis 1 (nf1)